Matinas BioPharma FY23 EPS $(0.11) Vs $(0.10) YoY
Matinas BioPharma FY23 EPS $(0.11) Vs $(0.10) YoY
2023 Financial Results
2023 年財務業績
Revenue for 2023 was $1.1 million, which was generated from the Company's research collaborations with BioNTech SE and Genentech Inc. This compares with revenue for 2022 of $3.2 million, which was generated from the Company's research collaboration with BioNTech SE.
2023年的收入爲110萬美元，來自公司與BioNTech SE和基因泰克公司的研究合作，而2022年的收入爲320萬美元，這來自公司與BioNTech SE的研究合作。
Total costs and expenses for 2023 were $24.9 million compared with $27.8 million for 2022. The decrease was primarily due to lower clinical trial expenses and lower professional and consulting fees. Income from selling unused New Jersey net operating losses (NOLs) and research and development tax credits was $0.5 million and $3.5 million for 2023 and 2022, respectively.
2023年的總成本和支出爲2490萬美元，而2022年爲2780萬美元。下降的主要原因是臨床試驗費用減少以及專業和諮詢費用降低。2023年和2022年，出售未使用的新澤西州淨營業虧損（NOL）和研發稅收抵免的收入分別爲50萬美元和350萬美元。
The net loss for 2023 was $22.9 million, or $0.11 per share, compared with a net loss for 2022 of $21.0 million, or $0.10 per share.
2023年的淨虧損爲2,290萬美元，合每股虧損0.11美元，而2022年的淨虧損爲2,100萬美元，合每股虧損0.10美元。
Cash, cash equivalents and marketable securities as of December 31, 2023 were $13.8 million compared with $28.8 million as of December 31, 2022. Based on current projections, the Company believes its cash position is sufficient to fund planned operations through the third quarter of 2024.
截至2023年12月31日，現金、現金等價物和有價證券爲1,380萬美元，而截至2022年12月31日爲2,880萬美元。根據目前的預測，該公司認爲其現金狀況足以爲2024年第三季度的計劃運營提供資金。